Accelerating Drug Discovery with AI
Actome is a next-generation platform combining artificial intelligence with systems biology to accelerate drug discovery, improve clinical outcomes, and significantly reduce experimental burden.
About Us
Actome is an AI-augmented clinical development platform designed to transform modern drug discovery and translational research. By integrating multi-modal biological data including in vitro, in vivo, and clinical datasets with advanced computational biology and deep learning, Actome enables faster, smarter, and more accurate decision-making across the drug development lifecycle. Our platform empowers researchers to generate actionable insights, predict clinical outcomes, and significantly reduce reliance on traditional trial heavy approaches. Actome has been successfully validated across oncology, immunology, and infectious disease programs, delivering accelerated timelines and unlocking new therapeutic opportunities.
Services
Actome offers a comprehensive suite of AI-driven services across the drug discovery continuum. Our in vitro and molecular capabilities include pathway modeling, target identification, drug interaction analysis, and IC50/EC50 prediction. In the preclinical space, we optimize animal studies through disease progression modeling, toxicity prediction, and experimental design refinement reducing animal dependency while maintaining scientific rigor. At a systemic level, we provide drug-drug interaction analysis, biomarker discovery, off-target identification, and drug repurposing solutions across oncology and immunology, enabling organizations to maximize research output and pipeline efficiency.
Molecular & In Vitro Modeling:
- Protein structure prediction
- Drug interaction modeling
- PK profiling
In Vivo Modeling:
- Disease simulation
- Toxicity prediction
- Reduced animal usage
System-Level Research:
- DDI prediction
- Biomarker discovery
- Drug repurposing
Use Cases
- Pharma companies
- Biotech startups
- CROs
- Research institutions
Partnership Model
- Project-based
- Licensing
- Co-development
Our Technology
At the core of Actome is a proprietary hybrid intelligence engine that combines systems biology models with advanced AI and machine learning layers. This architecture allows us to simulate complex biological systems, predict drug-target interactions, and model pharmacokinetics and pharmacodynamics (PK/PD) with high precision. By bridging biological pathways with predictive analytics, Actome identifies off-target effects early, optimizes experimental design, and enhances overall research efficiency. Compared to conventional methods, our technology significantly reduces turnaround time, improves predictive accuracy, and minimizes costly experimental iterations.
Actome operates on a proprietary
hybrid technology architecture combining:
- • Systems Biology Models
(validated biological pathways & mechanisms) - • AI/ML Layers
(deep learning, predictive modeling, pattern recognition)
This fusion creates a multi-layered biological intelligence engine capable of:
- ✔ Simulating disease progression
- ✔ Predicting drug-target interactions
- ✔ Modeling PK/PD behavior
- ✔ Identifying off-target effects early
Why Actome
The global AI-driven drug discovery market is rapidly expanding, expected to reach over $10 billion by 2030, while the CRO industry continues strong growth. Despite this, over 90% of drug candidates fail in clinical stages due to poor efficacy prediction and toxicity risks. Actome addresses these challenges by combining AI with biological intelligence, positioning itself uniquely at the intersection of data, biology, and clinical strategy. Our platform delivers over 40% cost reduction and up to 70% faster turnaround times, while improving precision in predicting drug behavior and clinical outcomes. With regulatory shifts encouraging AI-based validation and reduced animal testing, Actome is well-positioned to lead the next generation of drug development.
Traditional approaches are:
- Time-consuming
- Cost-intensive
- Dependent on iterative lab testing
Actome enables:
- Faster Turnaround Time (TAT)
- Higher predictive accuracy
- Reduced experimental redundancy
Market Opportunity
Global Landscape
- The global AI in drug discovery market was valued at ~$1.5–2 billion (2023) and is projected to reach $9–12 billion by 2030
- The Contract Research Organization (CRO) market exceeds $75 billion globally, growing at ~8–10% CAGR
Over 90% of drug candidates fail in clinical stages, largely due to:
- Poor efficacy prediction
- Toxicity issues
- Incorrect target selection
Contact
Let’s accelerate your next
breakthrough.
- Book a demo
- Request pilot study
- Explore partnerships
Actome aims to become a central intelligence layer for global
drug discovery, enabling:
- • AI-first clinical development
- • Reduced dependency on animal models
- • Faster, safer, and more cost-effective therapeutics
Email Us
connect@actome.ai